Harvard Bioscience (HBI0) AI Stock Analysis

1 Followers

Harvard Bioscience

(Frankfurt:HBI0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring revenue baseA recurring revenue base of about 54% gives Harvard Bioscience repeat demand from installed workflows and routine laboratory use. This can make revenue more resilient than relying solely on infrequent capital-equipment purchases and supports ongoing customer relationships over the next several quarters.

Negative Factors

High financial leverageA materially weakened equity base relative to debt reduces financial flexibility and increases the company’s sensitivity to operating setbacks. Persistent losses could make deleveraging harder, while the elevated leverage burden may constrain investment, acquisitions, and other capital-allocation choices.

Harvard Bioscience (HBI0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 42.94M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -3.6
Beta (1Y): 1.38
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 328
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Harvard Bioscience Business Overview & Revenue Model

Company Description

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular techn...

Harvard Bioscience Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Mar 11, 2027

Earnings Call SentimentPositive

The call was broadly positive, supported by 8% third-quarter revenue growth, strong demand across CRO, biopharma, organoid, fluidics, respiratory and China businesses, commercial-channel momentum, and progress on Project Viking. However, profitability metrics weakened because of unfavorable product and channel mix, operating expenses normalized, Europe and academic markets remained challenged, cash generation was negative through nine months, and full-year adjusted EBITDA growth guidance was reduced. Overall, the number and strength of the operating and growth highlights outweighed the financial and regional challenges.

Positive Updates

Strong Third-Quarter Revenue Growth

Revenue was $22.2 million, up 8% year-over-year and toward the high end of guidance, marking the second consecutive quarter of strong revenue growth. Growth was attributed primarily to continued CRO demand and robust distribution-partner sales.

Negative Updates

Gross Margin at Low End of Guidance

Adjusted gross margin was 57.1%, at the low end of the outlook range, due to greater demand for lower-margin legacy products, higher distribution-channel sales and continued strength in China, where margins are lower.

Company Guidance

Management reaffirmed full year 2026 revenue growth guidance of 3% to 5% and an adjusted gross margin target of 57% to 59%, while lowering full year adjusted EBITDA growth guidance from 6% to 10% to negative 1% to 4%. For the fourth quarter, it expects revenue between $23.7 million and $25.5 million, at the midpoint of $24.6 million, representing mid-single year-over-year revenue growth, adjusted gross margin between 59% and 61%, and adjusted EBITDA between $3.8 million and $4.2 million, which represents 5% growth at the midpoint; management is guiding to EBITDA growth in Q4 at the midpoint of its outlook. Project Viking remains on target for completion in the first quarter of 2027 and is expected to generate $3 million in cost savings in 2027 and $4 million annually thereafter, with savings of basically $1 million a quarter starting in quarter 2; management said it expects to be in the 60% range for gross margin in '27, and expects probably by midyear next year to be fully launching the BTX bioproduction product.

Harvard Bioscience Risk Analysis

Harvard Bioscience disclosed 27 risk factors in its most recent earnings report. Harvard Bioscience reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Harvard Bioscience Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:HBI0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLSS	44Neutral	$26.29M	-7.03	-122.29%	―	3.93%	48.18%
RVP	41Neutral	$16.62M	-4.65	-4.59%	―	-11.16%	59.85%
NXGL	40Underperform	$11.64M	-0.27	-133.10%	―	3.38%	-78.48%

* Healthcare Sector Average

Performance Comparison

DE:HBI0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:HBI0	Harvard Bioscience	4.08	-2.02	-33.11%
RVP	Retractable Technologies	0.56	-0.27	-32.89%
MLSS	Milestone Scientific Inc	0.31	-0.01	-1.60%
NXGL	Nexgel, Inc.	3.88	-32.92	-89.46%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Harvard Bioscience AI Stock Analysis